25 November 2024 In what could be construed to be India's quest for pharmaceutical supremacy, a clarion call has been made for the country to set its indigenous standards.
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
South African-Australian private equity firm LeapFrog Investments has announced the close of its fourth fund (Fund IV), with commitments and designated co-investments totalling $1.02 billion. 26 November 2024
Pyxis Oncology has announced encouraging preliminary data from a Phase I trial of PYX-201, its lead antibody-drug conjugate (ADC), in solid tumors. 26 November 2024
Spanish HIV focused immunotherapies company AELIX Therapeutics, a spin-off of IrisCaixa, has announced the acquisition of its investigational assets related to the HTI therapeutic HIV vaccine by US antiviral specialist Gilead Sciences. 26 November 2024
US biopharma Biohaven has provided an update regarding the taldefgrobep alfa development programs in spinal muscular atrophy (SMA) and obesity. 25 November 2024
Cassava Sciences, a US biotech developing a novel, investigational treatment for Alzheimer’s disease (AD) dementia, was trading 83% lower at midday on Thursday. 25 November 2024
Positive top-line results from the Phase III ZENITH study evaluating Winrevair (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH, WHO Group 1) functional class (FC) III or IV at high risk of mortality, were released today by US pharma giant Merck & Co. 25 November 2024
The US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for belantamab mafodotin in combinations with bortezomib plus dexamethasone (BorDex [BVd]) and pomalidomide plus dexamethasone (PomDex [BPd]) for multiple myeloma patients who have received at least one prior line of therapy. 25 November 2024
The US Food and Drug Administration (FDA) has approved Imkeldi (imatinib) oral solution, the first oral liquid form of imatinib to treat certain forms of leukemia and other cancers, from privately-held US-Ireland-based pharmaceutical company Shorla Oncology. 25 November 2024
Specialist pre-clinical contract research organization (CRO) and ion channel screening company Metrion Biosciences has announced the appointment of Lee Patterson as its new chief executive. 25 November 2024
Levothyroxine, a widely prescribed treatment for hypothyroidism, may contribute to bone loss in older adults, according to new research presented at the Radiological Society of North America’s (RSNA) annual meeting. 25 November 2024
StemCyte, a subsidiary of StemCyte International, has secured approval from the US Food and Drug Administration for Regenecyte, a cord blood-derived stem cell therapy. 25 November 2024
A patient in Neurogene’s ongoing Phase I/II trial for Rett syndrome—who was dosed on November 5 with 3E15 vg of NGN-401—has now died from a treatment-related serious adverse event (SAE). 25 November 2024
Sino-American oncology company BeOne Medicines, until now known as BeiGene, has entered into a settlement agreement with MSN Pharmaceuticals and MSN Laboratories Private resolving patent litigation related to MSN’s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Brukinsa (zanubrutinib) in the USA. 25 November 2024
In what could be construed to be India's quest for pharmaceutical supremacy, a clarion call has been made for the country to set its indigenous standards. 25 November 2024
Lexicon Pharmaceuticals has announced a major strategic shift, prioritizing its late-stage pipeline following a rejection by the US Food and Drug Administration (FDA). 25 November 2024
More positive data for Eli Lilly’s weight loss candidate tirzepatide will boost interest in the product, as the US regulator warns of supply shortages at certain doses. 28 July 2023
French drugmaker Sanofi has reported net sales for the second quarter of 2023 of $9.9 billion euros ($10.9 billion), a 1.5% fall, with net income of 1.4 billion euros and earnings per share (EPS) of 1.15 euros. 28 July 2023
Alexion, the rare disease business of UK pharma major AstraZeneca, has entered a definitive purchase and licence agreement for a portfolio of pre-clinical gene therapy programs and enabling technologies from US pharma giant Pfizer. 28 July 2023
US House and Senate Committees this week passed legislation to control the way pharmacy benefit managers (PBMs) can profit by increasing drug price. 28 July 2023
French drugmaker Ipsen has reported a 7.2% increase in revenues in the first half of the year, driven in part by newly-acquired medicines Bylvay (odevixibat) and Tazverik (tazemetostat). 27 July 2023
Shares of US pharma major AbbVie were up 3.6% at $147.02 in early trading, after the company announced financial results for the second quarter ended June 30, 2023. 27 July 2023
In anticipation of regulatory clearance for its proposed $43 billion acquisition of Seagen, US pharma giant Pfizer today announced a reorganization of its R&D team to create a leading company in the battle against cancer. 27 July 2023
Belgium’s largest pharma company UCB has posted a downbeat set of financials for the first half of 2023, with revenues falling 11% to 2.6 billion euros ($2.9 billion). 27 July 2023
UK pharma major AstraZeneca this morning revealed that Soliris (eculizumab) has been approved in the European Union (EU) for expanded use. 27 July 2023
Swiss pharmaceutical giant Roche this morning revealed that sales for the first half of 2023 had dropped 2% to 29.78 billion Swiss francs ($33.01 billion), or -8% in franc terms. 27 July 2023
US dermatology specialist Verrica Pharmaceuticals announced the closing of the previously announced $125 million debt financing with OrbiMed, a leading healthcare investment firm. 27 July 2023
Japan’s largest pharma company Takeda today announced strong financial results for the first quarter of fiscal year 2023 (period ended June 30, 2023). The firm’s edged up 0.7% to 4,401 yen following the news. 27 July 2023
The US Food and Drug Administration (FDA) yesterday approved Xdemvy (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis. 26 July 2023
The US Food and Drug Administration (FDA) has granted approval of Balfaxar (prothrombin complex concentrate, human-lans) for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, eg, warfarin) therapy in adult patients with need for urgent surgery or invasive procedures. 26 July 2023
Sales and profits at GSK beat expectations in the second quarter, with the firm reporting respectively a 4% and 8% increase from the same period of last year. 26 July 2023
Swiss clinical-stage biotech AC Immune today announced the appointment of Nuno Mendonca as its new chief medical officer of the neurodegenerative diseases specialist. 26 July 2023
US cell therapy developer SQZ Biotechnologies saw its shares close down almost 6% at $0.10 yesterday, after it revealed that Swiss pharma giant Roche has decided not to excercise its option for HPV 16 positive solid tumors under the SQZ-APC-HPV program. 26 July 2023